

Japan's NEC forges clinical development of Neoantigen Cancer Vaccine

05 March 2024 | News

Advance Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050 with Transgene and BostonGene



Japan's NEC Corporation, AI and digital tech firm along with Transgene, which develops virus-based immunotherapies for cancer, and BostonGene Corporation, a AI-based molecular and immune profiling firm, have further expanded their collaboration to conduct a randomized Phase I/II trial of TG4050, an individualized therapeutic vaccine for head and neck cancer patients.

BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services. The partnership with BostonGene will enable fast turnaround of next-generation sequencing (NGS) data, and sophisticated analytics will enable comprehensive profiling of patient immune contexture.

TG4050, a personalized immunotherapy designed to stimulate the immune system of patients to induce a neoantigen specific T-cell response that can recognize and destroy tumor cells, is based on Transgene's myvac® platform and powered by NEC's AI-driven Neoantigen Prediction System.

"The combined expertise of Transgene, NEC and BostonGene will continue to provide a streamlined pipeline for the timely delivery of patient-tailored vaccines as well as data to guide the future development of new personalized treatment options, elevating the standard of care for head and neck cancer patients," said Masamitsu Kitase, Corporate SVP and Head of the Healthcare and Life Sciences Division at NEC Corporation.